This study reveals the potential of engineered phage-IL-12 therapy in melanoma, enhancing immune response and tumor destruction in aggressive cancer models.

A team at the Peter Mac is planning for first-in-human trials in five years, hoping this new therapy will eschew the ...

Their lead candidate, CBT300, is designed to target and strip away a key protective mechanism cancer cells use to evade treatment, a heat shock protein called GRP78. The Davidsons’ story ...